Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00526318
First received: September 5, 2007
Last updated: August 6, 2013
Last verified: August 2011

September 5, 2007
August 6, 2013
January 2007
December 2012   (final data collection date for primary outcome measure)
Event-free survival (EFS) [ Designated as safety issue: No ]
Event-free survival (EFS)
Complete list of historical versions of study NCT00526318 on ClinicalTrials.gov Archive Site
  • Overall survival (OS) [ Designated as safety issue: No ]
  • Impact of well established clinical and molecular risk factors on EFS and OS [ Designated as safety issue: No ]
  • Early response, measured after 2 courses of induction chemotherapy [ Designated as safety issue: No ]
  • Response to induction therapy, measured before autologous stem cell transplantation [ Designated as safety issue: No ]
  • Toxicity during the first 2 courses and the last 6 courses of induction chemotherapy [ Designated as safety issue: Yes ]
  • Impact of the extent of initial and best surgery on outcome and frequency of complications [ Designated as safety issue: No ]
  • Acute and late toxicity of radiotherapy [ Designated as safety issue: Yes ]
  • Correlation of MIBG activity with whole-body radiation dose [ Designated as safety issue: No ]
  • Molecular markers (MYCN and status of chromosome 1p and 11q) [ Designated as safety issue: No ]
  • Overall survival (OS)
  • Impact of well established clinical and molecular risk factors on EFS and OS
  • Early response, measured after 2 courses of induction chemotherapy
  • Response to induction therapy, measured before autologous stem cell transplantation
  • Toxicity during the first 2 courses and the last 6 courses of induction chemotherapy
  • Impact of the extent of initial and best surgery on outcome and frequency of complications
  • Acute and late toxicity of radiotherapy
  • Correlation of MIBG activity with whole-body radiation dose
  • Molecular markers (MYCN and status of chromosome 1p and 11q)
Not Provided
Not Provided
 
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
Trial Protocol for the Treatment of Children With High Risk Neuroblastoma (NB2004-HR)

RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or by killing them. It also prepares the patient's bone marrow for the stem cell transplant. The stem cells are given to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving isotretinoin after transplant may kill any remaining tumor cells. It is not yet known which combination chemotherapy regimen is more effective when given before a stem cell transplant and isotretinoin in treating neuroblastoma.

PURPOSE: This randomized clinical trial is studying two different combination chemotherapy regimens to compare how well they work when given before a stem cell transplant and isotretinoin in treating young patients with high-risk neuroblastoma.

OBJECTIVES:

Primary

  • Compare the event-free survival of pediatric patients with high-risk neuroblastoma treated with standard induction chemotherapy vs topotecan hydrochloride-containing induction chemotherapy followed by myeloablative autologous stem cell transplantation and consolidation therapy with isotretinoin.

Secondary

  • Compare the overall survival of patients treated with these regimens.
  • Compare early response (complete response, very good partial response, partial response, mixed response, stable disease, and progression/relapse) after 2 courses of standard vs experimental induction chemotherapy (or after 60 days if the second course is not yet finished).
  • Compare response to standard vs experimental induction chemotherapy before autologous stem cell transplantation (or after 280 days if induction chemotherapy is not yet finished).
  • Compare the toxicity of standard vs experimental induction chemotherapy during courses 1 and 2 and the frequency of ≥ grade 3 toxicity during the last 6 courses of induction chemotherapy.
  • Compare the extent of initial surgery and best surgery (biopsy vs incomplete resection vs macroscopic complete resection) and the frequency of complications related to surgery (e.g., nephrectomy, bleeding, infection, or intestinal obstruction).
  • Compare the acute and long-term side effects of external-beam radiotherapy.
  • Correlate the activity of MIBG and whole-body radiation dose.
  • Collect and store tumor material in the tumor bank for future evaluation of other molecular markers (MYCN and status of chromosome 1p and 11q) and prognostic significant gene signatures.

OUTLINE: This is a multicenter study. Patients are stratified according to disease stage, lactate dehydrogenase (LDH) status, MYCN status, and age at diagnosis (stage 4 disease; LDH not elevated; any MYCN status; age at diagnosis 1-21 years vs stage 4 disease; LDH elevated; any MYCN status; age at diagnosis ≥ 1 but < 2 years vs stage 4 disease; LDH elevated; any MYCN status; age at diagnosis 2-21 years vs localized disease; MYCN amplification; age at diagnosis ≥ 6 months)

  • Induction chemotherapy: Patients are randomized to 1 of 2 induction chemotherapy arms.

    • Arm I (standard): Patients receive N5 chemotherapy comprising cisplatin IV continuously over 96 hours and etoposide phosphate IV continuously over 96 hours on days 1-4 and vindesine IV over 1 hour on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 9 and continuing until blood counts recover. Patients then receive N6 chemotherapy comprising vincristine IV over 1 hour on days 1 and 8, dacarbazine IV over 1 hour on days 1-5, ifosfamide IV continuously over 120 hours on days 1-5, and doxorubicin hydrochloride IV over 4 hours on days 6 and 7. Patients also receive G-CSF SC once daily beginning on day 10 and continuing until blood counts recover. Treatment with N5 and N6 chemotherapy alternates every 21 days for 6 courses (N5 chemotherapy is given in courses 1, 3, and 5 and N6 chemotherapy is given in courses 2, 4, and 6).
    • Arm II (experimental): Patients receive N8 chemotherapy comprising cyclophosphamide IV over 1 hour on days 1-7, topotecan hydrochloride IV continuously over 168 hours on days 1-7, and etoposide phosphate IV over 1 hour on days 8-10. Patients also receive G-CSF SC once daily beginning on day 12 and continuing until blood counts recover. Treatment with N8 chemotherapy repeats every 21 days for 2 courses. Patients then receive N5 chemotherapy alternating with N6 chemotherapy as in arm I.
  • Surgery: Patients may undergo secondary surgery after completion of 4 or 6 courses of induction chemotherapy but prior to radiotherapy.
  • Radiotherapy (131I-MIBG therapy and external-beam radiotherapy [EBRT]): Patients with active residual primary tumor after the completion of induction chemotherapy undergo ^131I-MIBG therapy* prior to autologous stem cell transplantation (ASCT) and EBRT after ASCT.

NOTE: *Patients with MIBG negative neuroblastoma at initial diagnosis will only receive EBRT.

  • Myeloablative ASCT: Patients receive melphalan IV over 30 minutes on days -8 to -5, etoposide phosphate IV over 4 hours on day -4, and carboplatin IV over 1 hour on days -4 to -2. Patients undergo reinfusion of CD34+ stem cells on day 0. Patients also receive G-CSF SC or IV over 4 hours once daily beginning on day 2 and continuing until blood counts recover.
  • Consolidation therapy (isotretinoin)*: Beginning 30 days after ASCT, patients receive oral isotretinoin once daily on days 1-14. Treatment repeats every 28 days for up to 6 courses. Beginning 3 months later, patients receive an additional 3 courses of isotretinoin.

NOTE: *Isotretinoin must not be given concurrently with radiotherapy

After completion of study treatment, patients are followed every 6 weeks for 1 year, every 3 months for 4 years, and then every 6 months thereafter.

Interventional
Not Provided
Allocation: Randomized
Primary Purpose: Treatment
Neuroblastoma
  • Biological: filgrastim
  • Drug: carboplatin
  • Drug: cisplatin
  • Drug: cyclophosphamide
  • Drug: dacarbazine
  • Drug: doxorubicin hydrochloride
  • Drug: etoposide phosphate
  • Drug: ifosfamide
  • Drug: isotretinoin
  • Drug: melphalan
  • Drug: topotecan hydrochloride
  • Drug: vincristine sulfate
  • Drug: vindesine
  • Procedure: autologous hematopoietic stem cell transplantation
  • Radiation: iobenguane I 131
  • Radiation: radiation therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
360
Not Provided
December 2012   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of neuroblastoma according to any of the following criteria:

    • Histological diagnosis from tumor tissue
    • Presence of distinct neuroblastoma cells in the bone marrow and elevated catecholamine metabolites (HVA, VMA) in blood or urine
  • High-risk disease, meeting 1 of the following criteria:

    • Stage 4 disease, regardless of the MYCN status (1-21 years of age)
    • Stage 1-3 or 4S disease with MYCN amplification (6 months -21 years of age)

PATIENT CHARACTERISTICS:

  • Not pregnant or nursing
  • Fertile patients must use effective contraception (hormonal contraception or intra-uterine device [IUD])

PRIOR CONCURRENT THERAPY:

  • No concurrent participation in another clinical trial that would preclude the interventions or outcome assessment of this clinical trial
  • No other concurrent anticancer therapy
Both
up to 21 Years
No
Germany,   Switzerland
 
NCT00526318
GPOH-NB2004-HR, CDR0000564820, UNI-KOELN-161, EU-20661
Not Provided
Not Provided
Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Not Provided
Study Chair: Frank Berthold, MD Children's Hospital Medical Center, Cincinnati
National Cancer Institute (NCI)
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP